Table 5.

Comparison of area under the curves for Week 12 endoscopic remission of Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease versus Simple Endoscopic Score for Crohn’s Disease.

Endoscopic remission at Week 12	Overall (n = 100)	p value	Adalimumab (n = 51)	p value	Placebo (n = 49)	p value
MM-SES-CD ≥ 20% reduction from baseline	0.73 (0.62-0.84)	0.002	0.72 (0.39-1.00)	<0.001	0.69 (0.56-0.83)	0.006
SES-CD ≥ 50% reduction from baseline	0.62 (0.51-0.72)		0.60 (0.27-0.94)		0.55 (0.43-0.67)
MM-SES-CD ≥ 40% reduction from baseline	0.69 (0.59-0.80)	<0.001	0.67 (0.33-1.00)	0.010	0.65 (0.52-0.77)	0.008
SES-CD ≥ 50% reduction from baseline	0.62 (0.51-0.72)		0.60 (0.27-0.94)		0.55 (0.43-0.67)
MM-SES-CD < 22.5	0.71 (0.60-0.81)	<0.001	0.67 (0.33-1.00)	<0.001	0.68 (0.55-0.81)	<0.001
SES-CD of 0	0.54 (0.51-0.57)		0.55 (0.51-0.60)		0.52 (0.49-0.55)
MM-SES-CD < 22.5	0.71 (0.60-0.81)	<0.001	0.67 (0.33-1.00)	0.648	0.68 (0.55-0.81)	<0.001
SES-CD < 4	0.61 (0.56-0.65)		0.66 (0.59-0.72)		0.53 (0.49-0.57)
MM-SES-CD < 22.5	0.71 (0.60-0.81)	<0.001	0.67 (0.33-1.00)	<0.001	0.68 (0.55-0.81)	<0.001
SES-CD < 3	0.56 (0.52-0.59)		0.58 (0.53-0.64)		0.52 (0.49-0.55)